Follow any specific post-care instructions provided by our staff.
It is part of the group of nutritional supplements
Semaglutide is a well-established treatment for type 2 diabetes
Side effects such as nausea, reflux, cramping, and constipation are common side effects that may limit use, too
Extensively validated for GLP-1, GIP, and GCGR receptor triple-agonist studies
What we know: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously Phase 2/3 trials show 24-29% weight loss at highest doses Side effects are similar to other incretin medications (mainly GI) It may be particularly effective for liver fat reduction FDA approval is potentially years away What to consider: Approved alternatives (semaglutide, tirzepatide) have established safety profiles "GLP-3" marketing may oversimplify or mislead Investigational drugs carry unknown long-term risks Quality control for compounded versions is variable Clinical trial results don't always translate to real-world outcomes The bigger picture: Retatrutide may represent a genuine advance in obesity treatmentthe data is genuinely impressive